- Ribbon cutting attended by the Prime Minister of the Republic
of Slovenia, Janez Janša
- Innovative products for the purification of advanced agents
such as mRNA or adenoviruses for the manufacture of vaccines or
therapeutics
AJDOVSCINA, Slovenia,
May 28, 2021 /PRNewswire/ --
Sartorius, a leading international partner of life science research
and the biopharmaceutical industry, will open its expanded
production facilities in Ajdovscina, Slovenia. The area for manufacturing and labs
will increase from 3,000 square meters to 6,200 square meters.
Today's ribbon cutting was attended by Janez Janša, Prime
Minister of the Republic of Slovenia, and the Ajdovscina Town Mayor
Tadej Beočanin. "The expansion is an
important step forward and will enable our business to develop and
grow to meet the requirements of our customers in a rapidly
expanding industry. It will particularly enhance our unique
offering for the manufacturing of gene therapies and other advanced
therapies," said Joachim Kreuzburg,
CEO of Sartorius. In 2021, Sartorius will invest more than
400 million euros in the expansion of
manufacturing capacities around the world to meet the high demand
from the growing biopharmaceuticals market.
With more than 140 employees at its plant in Ajdovscina,
Sartorius develops and manufactures market-leading products for
purification and analysis of large biomolecules, such as viruses,
plasmids and mRNA, which are used in vaccines as well as in cell
and gene therapies and other advanced therapies.
Background: In November 2020,
Sartorius acquired the Slovenian purification specialist BIA
Separations in Ajdovscina. Its technology for manufacturing-scale
purification is already used in production of the first
commercialized advanced therapeutics, and the company also has a
strong presence with such novel drug candidates in the clinical
pipeline.
Current image files
https://www.sartorius.com/en/company/newsroom/downloads-publications
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end
of 2020, nearly 11,000 people were employed at the Group's
approximately 60 manufacturing and sales sites, serving customers
around the globe.
Contact
Timo Lindemann
Corporate Communications
+49 (0)551.308.4724
timo.lindemann@sartorius.com
sartorius.com
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
Logo -
https://mma.prnewswire.com/media/1472792/Sartorius_Logo.jpg